Danziten
Danziten ingredients
| Active ingredient | Strength |
|---|---|
| Nilotinib | 95 mg/1, 71 mg/1 |
What Danziten is used for
The FDA lists the approved uses on the official label (below). In the EU, nilotinib is approved as Tasigna for:
Tasigna is indicated for the treatment of: adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib. Tasigna is indicated for the treatment of: adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available, paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Danziten
- Generic name
- Nilotinib
- Made by
- Azurity Pharmaceuticals, Inc.
- Forms
- Tablet
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA219293
- On the US market since
- 2024
Official information
- Danziten prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Nilotinib)
In India
- Nilotinib: 2 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Danziten?
Danziten (Nilotinib) is a cancer medicine made by Azurity Pharmaceuticals, Inc., approved by the US FDA.
What are the ingredients of Danziten?
Danziten contains Nilotinib (95 mg/1, 71 mg/1).
Is Danziten approved in Europe?
The same active substance is approved in the EU as Tasigna.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA